Biogen: all 548 studies

Page 3 of 6. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known WellWithdrawnNCT05764122Phase 2
• A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) ParticipantsTerminatedNCT05701423
• A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesActive, not recruitingNCT05688436
• A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaCompletedNCT05658484Phase 4
• Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)CompletedNCT05655507Phase 1
• Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379
• A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene AbeparvovecActive, not recruitingNCT05575011Phase 1
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT05532163Phase 4
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusActive, not recruitingNCT05531565Phase 2/3
• A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeActive, not recruitingNCT05399888Phase 2
• Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular AtrophyCompletedNCT05354414Not applicable
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80CompletedNCT05348785Phase 2
• A Study for Tysabri Participant PreferenceCompletedNCT05304520
• TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated ParticipantsCompletedNCT05236777
• A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian ParticipantsCompletedNCT05229562Phase 1
• A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy VolunteersCompletedNCT05216887Phase 1
• Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination StudyTerminatedNCT05197699
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy ParticipantsCompletedNCT05195008Phase 1
• A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3TerminatedNCT05160558Phase 1
• A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy ParticipantsCompletedNCT05152485Phase 1
• A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsCompletedNCT05148481Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy ParticipantsCompletedNCT05127564Phase 1
• A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male SubjectsCompletedNCT05119790Phase 1
• A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular DisordersCompletedNCT05109637Not applicable
• A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue DamageCompletedNCT05106465
• An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the USTerminatedNCT05097131
• A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)Active, not recruitingNCT05067790Phase 3
• An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal AgingTerminatedNCT05058950
• MS PATHS COVID-19 Questionnaire Data Linkage Sub-StudyCompletedNCT05058729
• Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921
• A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy SubjectsCompletedNCT05005338Phase 1
• Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral SclerosisApproved for marketingNCT04972487
• A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusActive, not recruitingNCT04961567Phase 3
• Exploring Diroximel Fumarate Real-world Experience in Canada and IsraelTerminatedNCT04948606
• A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related EpilepsyCompletedNCT04924153
• A Study to Assess Absolute Bioavailability of Aducanumab in Healthy VolunteersCompletedNCT04924140Phase 1
• A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusActive, not recruitingNCT04895241Phase 3
• Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS SymptomsActive, not recruitingNCT04856982Phase 3
• Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsCompletedNCT04832399
• Natural Disease Progression in Participants With ChoroideremiaCompletedNCT04795206
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDCompletedNCT04770545Phase 3
• Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple SclerosisCompletedNCT04756700Not applicable
• Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by TecfideraCompletedNCT04756687
• A Study to Assess Choroideremia (CHM) Health OutcomesCompletedNCT04750785
• Study of Diroximel Fumarate in the Real-World SettingTerminatedNCT04746976
• Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)CompletedNCT04733040Phase 2
• A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)CompletedNCT04729907Phase 3
• C3G/Primary IC-MPGN EAPApproved for marketingNCT04729062
• Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support ProgramCompletedNCT04655222
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult ParticipantsCompletedNCT04593121Phase 1
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian ParticipantsCompletedNCT04571424Phase 1
• Study of BIIB091 Formulations in Healthy ParticipantsCompletedNCT04564612Phase 1
• A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)CompletedNCT04488133Phase 4
• Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium InjectionCompletedNCT04419233
• Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)Active, not recruitingNCT04317794
• Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04288856Phase 1
• Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEPCompletedNCT04221191
• Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHSCompletedNCT04145284
• Scan-Rescan Sub-Study of MS PATHSCompletedNCT04123353
• Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic PolyneuropathyWithdrawnNCT04106050Phase 1
• Angelman Syndrome (AS) Biomarker StudyCompletedNCT04103333Early Phase 1
• A Real-world Study of Imraldi® UseCompletedNCT04089514
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsCompletedNCT04079101Phase 1
• Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)WithdrawnNCT04079088Phase 2
• A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy ParticipantsCompletedNCT04068532Phase 1
• Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseCompletedNCT04056689Phase 1
• A Clinical Drug-Drug Interaction (DDI) Study With OmaveloxoloneCompletedNCT04008186Phase 1
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT03958877Phase 3
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral SclerosisCompletedNCT03945279Phase 1
• A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult ParticipantsCompletedNCT03943056Phase 1
• A Human AME Study for OmaveloxoloneCompletedNCT03931590Phase 1
• Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple SclerosisTerminatedNCT03926637
• A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT03902002Phase 1
• Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic AtrophyCompletedNCT03777332Phase 1
• A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy AdultsCompletedNCT03764488Phase 1
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's DiseaseTerminatedNCT03716570Phase 1
• A Pharmacokinetic Study of Omaveloxolone in Healthy VolunteersCompletedNCT03664453Phase 1
• One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyCompletedNCT03662919
• 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaWithdrawnNCT03637387Phase 3
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral SclerosisCompletedNCT03626012Phase 1
• Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401No longer availableNCT03593499
• Safety and PK/PD of RTA 1701 in Healthy AdultsCompletedNCT03579030Phase 1
• Pegcetacoplan Long Term Safety and Efficacy Extension StudyCompletedNCT03531255Phase 3
• Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy ParticipantsCompletedNCT03454126Phase 1
• Tysabri Observational Cohort Study - Multiple Sclerosis (MS) RegistriesCompletedNCT03399981
• Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074CompletedNCT03385525Phase 1
• A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple SclerosisCompletedNCT03347370
• Efficacy and Safety Study of BIIB074 in Participants With Small Fiber NeuropathyTerminatedNCT03339336Phase 2
• Benepali® PEN Patient Satisfaction SurveyCompletedNCT03327454
• A Drug Interaction Study of BIIB074 and an Oral Contraceptive RegimenCompletedNCT03324685Phase 1
• A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia ModelCompletedNCT03284931Phase 1
• Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy AdultsCompletedNCT03264079Phase 1
• Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.CompletedNCT03224793Phase 1
• Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedNCT03177083Phase 4
• Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From EnbrelCompletedNCT03100734
• Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With PlegridyCompletedNCT03091569Phase 4
• Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)CompletedNCT03088956
• 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaWithdrawnNCT03070132Phase 3
• Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's DiseaseCompletedNCT03056729Phase 1
• MS PATHS Normative Sub-StudyCompletedNCT02996084

← Biogen overview and focus areas